Please login to the form below

Not currently logged in
Email:
Password:

Targovax appoints chief financial officer

Dr Erik Digman Wiklund succeeds Oystein Soug

Targovax Dr Erik Digman WiklundTargovax has appointed Dr Erik Digman Wiklund as its new chief financial officer from April this year, succeeding Oystein Soug who became the firm's chief executive officer in November 2016.

Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.

He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey & Company's pharma and healthcare practice.

Soug said: “We are delighted to announce the appointment of Erik as our new chief financial officer.

“He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background.

“Erik's breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients' own immune system to fight cancer.”

18th January 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...
Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...

Infographics